Pathos AI, BMS and Tempus team up on AI neuroscience discovery

What's the deal? New York-based Pathos AI has announced multi-year collaborations with Bristol-Myers Squibb (BMS) and Tempus to build an AI-driven drug discovery effort for Alzheimer's disease and other neurological conditions, announced 25 October 2026. Tempus will assemble a large de-identified dataset spanning hundreds of thousands of neurological patients; Pathos will license it under a five-year, $55 million agreement and interrogate it with its agentic AI platform, Pathos Foundry, which designs and adapts clinical trials in real time based on probability-of-success calculations.

Why it matters: BMS brings neuroscience drug-development expertise and has secured exclusive three-year rights to apply Pathos Foundry to its neuroscience programs, with broader non-exclusive access across its portfolio. The collaboration is an example of the emerging AI-native model of drug development: instead of a single lab chasing one hypothesis, the partners combine longitudinal patient data, AI that reasons over it at scale, and drug-development expertise to generate and test hypotheses on disease biology.

Context: Pathos, a clinical-stage company, built and validated this approach in oncology, where it has a pipeline spanning prostate cancer, multiple myeloma, non-small-cell lung cancer, breast cancer and TROP2/HER3-expressing solid tumors. The company's CEO Iker Huerga said the collaborations bring together data, AI and drug-development expertise to turn insight into medicines.

Read more: BioSpace, 26 Oct 2026